Regulations

FDA DBT reclassification reviewed by a breast imaging team

August 10, 2026

FDA Proposes a New Regulatory Path for Digital Breast Tomosynthesis

FDA has proposed moving digital breast tomosynthesis systems from Class III to Class II. Here is what the change could mean for manufacturers and mammography facilities—and what would remain unchanged….